


LITERATÚRA

- Dale W, Bilir P, Han M, et al. The role of anxiety in prostate carcinoma: a structured review of the literature. *Cancer*. 2005;104(3):467-478. doi:10.1002/cncr.21198.
- Bernal-Soriano MC, Parker LA, López-Garrigos M, et al. Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol. *Medicine*. 2019;98(40):e17451. doi:10.1097/MD.00000000000017451.
- Perera M, Manning T, Finelli A, et al. Management of men with previous negative prostate biopsy. *Curr. Opin. Urol*. 2016;26(5):481-487. doi:10.1097/MOU.0000000000000315.
- Dimmen M, Vlatkovic L, Hole KH, et al. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies. *BJU Int*. 2012;110(2 Pt 2):E69-E75. doi:10.1111/j.1464-410X.2011.10759.x.
- Heidrich I, Ačkar L, Mossahebi Mohammadi P, et al. Liquid biopsies: Potential and challenges. *Int. J. Cancer*. 2021;148(3):528-545. doi:10.1002/ijc.33217.
- Available from: <https://gco.iarc.fr/>
- Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. *Biomark. Med*. 2011;5(4):515-526. doi:10.2217/bmm.11.53.
- Tkac J, Bertok T, Hires M, et al. Glycomics of prostate cancer: updates. *Expert Rev. Proteomics*. 2019;16(1):65-76. doi:10.1080/14789450.2019.1549993.
- Petrosyan A. Onco-Golgi: Is Fragmentation a Gate to Cancer Progression? *Biochem Mol Biol J*. 2015;1(1):16. doi:10.21767/2471-8084.100006.
- Bertok T, Jane E, Chrenekova N, et al. Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms. *Glycoconj. J*. 2020;37(6):703-711. doi:10.1007/s10719-020-09958-4.
- Available from: <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019185515>.
- Tkac J, Gajdosova V, Hroncekova S, et al. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. *Interf. Focus*. 2019;9(2). doi.org/10.1098/rsfs.2018.0077.
- Chen Z, Gulzar ZG, St. Hill CA, et al. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. *Prostate*. 2014;74:1059-1067. doi.org/10.1002/pros.22826.
- Bertok T, Jane E, Bertokova A, et al. Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. *Cancers*. 2020;12(10):2988. doi:10.3390/cancers12102988.
- Bertokova A, Bertok T, Jane E, et al. Detection of N, N-diacyllactosamine (LacdiNAc) containing free prostate-specific antigen for early-stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. *Bioorg. Med. Chem*. 2021;39:116156. doi:10.1016/j.bmc.2021.116156.
- Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann. Oncol*. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011.
- Mainwaring JM, Walker LM, Robinson JW, et al. The Psychosocial Consequences of Prostate Cancer Treatments on

Obr. 3. Diagnostický algoritmus CaP. Zelenou zvýraznené sú aktuálne body aplikovania Giasay testu na zlepšenie súčasnej diagnostiky a spresnenie indikácie na biopsiu prostaty. Giasay test je využiteľný najmä ako second opinion test pri podozrení na možnú prítomnosť CaP (pomocou rutinných testov ako tPSA, DRE a PSA denzita) alebo ako možnosť monitoringu pacienta počas liečby (pred prostatektómiou)



PCa – potvrdená rakovina prostaty, DRE – digital rectal examination/digitálne rektálne vyšetrenie, US – ultrasound/ultrazvuk, MRI – magnetic resonance imaging/magnetická rezonancia, PET CT – positron emission tomography-computed tomography/pozitronová emisná tomografia v kombinácii s počítačovou tomografiou, DX – diagnostika, PI RADS – prostate imaging reporting and data system/systém na vyhodnocovanie dát a zobrazenia prostaty, TRUS – transrectal ultrasonography/transrektálne ultrazvukové vyšetrenie prostaty, Th – terapia, BPH – benign prostatic hyperplasia/benígna prostatická hyperplázia

Body Image, Sexuality, and Relationships. *Front. Psychol*. 2021;12:765315. doi:10.3389/fpsyg.2021.765315.

of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. *BMC Cancer*. 2020;20(1):757. doi:10.1186/s12885-020-07244-y.

Houédy N, Rébillard X, Bouvet S, et al. Impact on quality